TABLE 2.
PLWH |
Uninfected controls |
|||||
T-cell subsets | Model 1 | p | Model 2 | p | Model 1 | p |
CD4+ activation | −6.7% (−9.5; −3.9) | <0.001 | −5.8 (−8.6; −1.9) | 0.001 | 2.02% (−14.8; 22.2) | 0.821 |
CD8+ activation | −2.9% (−4.8; 0.0) | 0.028 | −2.0 (−4.9; 1.0) | 0.297 | 7.3% (−7.8; 24.6) | 0.347 |
CD4+ senescent | 16.2% (7.3; 27.1) | 0.001 | 25.9 (13.9; 39.1) | <0.001 | 46.2% (−3.0; 120.3) | 0.074 |
CD8+ senescent | 11.6% (6.2; 16.2) | <0.001 | 16.2 (10.5; 22.1) | <0.001 | 22.14% (−4.9; 56.8) | 0.122 |
CD4+ apoptotic | 18.5% (10.5; 25.9) | <0.001 | 20.9 (11.6; 31.0) | <0.001 | 18.5% (−10.4; 58.4) | 0.239 |
CD8+ apoptotic | 12.8% (8.3; 17.4) | <0.001 | 16.2 (10.5; 20.9) | <0.001 | 24.6% (0.0; 55.3) | 0.061 |
Model 1 was adjusted for sex, BMI group and smoking status. Model 2 was further adjusted for CD4+ nadir and time on cART. All T-cell subsets were log transformed before analyzed. Activation (CD38+ HLA-DR+), senescent (CD28-CD57+), and apoptotic (CD28-CD95+).